Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Callahan

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
The New England Journal of Medicine|August 11, 2006
High-dose atorvastatin after stroke or transient ischemic attackPierre Amarenco, Julien Bogousslavsky, Alfred Callahan, et al.
Atherosclerosis|October 31, 2008
Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trialPierre Amarenco, Larry B Goldstein, Alfred Callahan, et al.
Stroke|February 21, 2009
Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypesPierre Amarenco, Oscar Benavente, Larry B Goldstein, et al.
Archives of Neurology|June 15, 2011
Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trialAlfred Callahan, Pierre Amarenco, Larry B Goldstein, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
The New England Journal of Medicine|August 11, 2006
High-dose atorvastatin after stroke or transient ischemic attackPierre Amarenco, Julien Bogousslavsky, Alfred Callahan, et al.
Atherosclerosis|October 31, 2008
Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trialPierre Amarenco, Larry B Goldstein, Alfred Callahan, et al.
Stroke|February 21, 2009
Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypesPierre Amarenco, Oscar Benavente, Larry B Goldstein, et al.
Archives of Neurology|June 15, 2011
Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trialAlfred Callahan, Pierre Amarenco, Larry B Goldstein, et al.
Pageof 2